Karl-Erik Andersson

How many drugs for LUTS due to BPH are too many?

Dysregulation of cGMP-dependent protein kinase 1 (PKG-1) impairs erectile function in diabetic rats: influence of in vivo gene therapy of PKG1alpha.

Effect of melatonin on age associated changes in Guinea pig bladder function.

Urodynamic effects of a novel EP(1) receptor antagonist in normal rats and rats with bladder outlet obstruction.

Regenerative pharmacology: the future is now.

Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats.

Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats--effects of bladder outlet obstruction and intravesical PGE2.

Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system.

Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract.

Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.

Microarray analysis of exstrophic human bladder smooth muscle.

Muscarinic receptor antagonists for overactive bladder.

Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations.

Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder.

A mutation in the inner mitochondrial membrane peptidase 2-like gene (Immp2l) affects mitochondrial function and impairs fertility in mice.

Melatonin restores impaired contractility in aged guinea pig urinary bladder.

Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo.

Microarray analysis of bladder smooth muscle from patients with myelomeningocele.

Voiding pattern analysis as a surrogate for cystometric evaluation in uroplakin II knockout mice.

Transient receptor potential A1 (TRPA1) activity in the human urethra--evidence for a functional role for TRPA1 in the outflow region.

Angiogenic gene modification of skeletal muscle cells to compensate for ageing-induced decline in bioengineered functional muscle tissue.

Effects of natriuretic peptides on intracavernous pressure and blood pressure in conscious rats.

Signal transduction pathways of muscarinic receptor mediated activation in the newborn and adult mouse urinary bladder.

A canine model of irreversible urethral sphincter insufficiency.

Effects of long-term dietary soy treatment on female urethral morphology and function in ovariectomized nonhuman primates.

Urine derived cells are a potential source for urological tissue reconstruction.

Are female lower urinary tract symptoms alleviated by alpha-adrenoreceptor antagonists?

Role of alpha1-adrenergic receptors in detrusor overactivity induced by cold stress in conscious rats.

Urothelial effects of oral agents for overactive bladder.

Substantial detrusor overactivity in conscious spontaneously hypertensive rats with hyperactive behaviour.

Localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity.

Smooth-muscle-specific gene transfer with the human maxi-k channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys.

Premature ejaculation: focus on therapeutic targets.

Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder.

Alterations in bladder function associated with urothelial defects in uroplakin II and IIIa knockout mice.

An extract (THC-002) of Ba-Wei-Die-Huang-Wan inhibits expression of tachykinins, and P2X3 and TRPV1 receptors, and inhibits ATP-induced detrusor overactivity in spontaneously hypertensive rats.

Receptor-induced phasic activity of newborn mouse bladders is inhibited by protein kinase C and involves T-type Ca2+ channels.

Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence.

Metrics for evaluation of age-related changes in erectile capacity in a rodent model.

Stimulation of skin menthol receptors stimulates detrusor activity in conscious rats.

A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature.

Vardenafil-induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder.

Transient receptor potential A1 and cannabinoid receptor activity in human normal and hyperplastic prostate: relation to nerves and interstitial cells.

Prostanoid receptor subtypes: new targets for OAB drugs?

Pharmacotherapy of the overactive bladder.

Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications.

Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction.

Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.

Bladder dysfunction in a new mutant mouse model with increased superoxide--lack of nitric oxide?

Detrusor myocyte activity and afferent signaling.

Voiding effects mediated by α2-adrenoceptors in the anaesthetized male rat.

Bladder afferent signaling: recent findings.

Words of wisdom. Re: Spontaneous release of acetylcholine from autonomic nerves in the bladder.

Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats.

Early stages of in situ bladder regeneration in a rodent model.

TRPA1 receptor induced relaxation of the human urethra involves TRPV1 and cannabinoid receptor mediated signals, and cyclooxygenase activation.

Impaired bladder function in aging male rats.

Development of bladder dysfunction in a rat model of dopaminergic brain lesion.

Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction.

Effects of intravesical instillation of ATP on rat bladder primary afferent activity and its relationship with capsaicin-sensitivity.

Detrusor underactivity/underactive bladder: new research initiatives needed.

Comparison of the effects of oestrogen deficiency and old age on primary bladder afferent activity and voiding behaviour in the ageing female rat.

Selection of a control rat for conscious spontaneous hypertensive rats in studies of detrusor overactivity on the basis of measurement of intra-abdominal pressures.

β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder.

Relation between expression of α(1)-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms.

Future sexual medicine physiological treatment targets.

Thromboxane A2 induces contraction of human prostate smooth muscle by Rho kinase- and calmodulin-dependent mechanisms.

EAU guidelines on urinary incontinence.

The role of the transient receptor potential (TRP) superfamily of cation-selective channels in the management of the overactive bladder.

Cannabinor, a selective cannabinoid-2 receptor agonist, improves bladder emptying in rats with partial urethral obstruction.

Antimuscarinic mechanisms and the overactive detrusor: an update.

Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E(2)-induced detrusor overactivity in conscious female rats.

Exploration of therapeutic targets for sexual dysfunctions: lessons learned from the failed stories.

Effect of the SK/IK channel modulator 4,5-dichloro-1,3-diethyl-1,3-dihydro-benzoimidazol-2-one (NS4591) on contractile force in rat, pig and human detrusor smooth muscle.

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.

Coupling of α1-adrenoceptors to ERK1/2 in the human prostate.

α1-adrenoceptor activation induces phosphorylation of β2-adrenoceptors in human prostate tissue.

Characterization of urine-derived stem cells obtained from upper urinary tract for use in cell-based urological tissue engineering.

Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.

Rodent models for urodynamic investigation.

Researching bladder afferents-determining the effects of β(3) -adrenergic receptor agonists and botulinum toxin type-A.

Beta3-adrenoceptors in the rat sacral spinal cord and their functional relevance in micturition under normal conditions and in a model of partial urethral obstruction.

Exogenously administered bombesin and gastrin releasing peptide contract the female rat urethra in vivo and in vitro.

Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting.

Improving voiding efficiency in the diabetic rat by a 5-HT1A serotonin receptor agonist.

Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA).

Peer review: "a critique of the critics".

Prospective pharmacologic therapies for the overactive bladder.

Persistent detrusor overactivity in rats after relief of partial urethral obstruction.

Therapeutic targets for premature ejaculation.

Pelvic floor disorders: linking genetic risk factors to biochemical changes.

Neurourology and Urodynamics. Editorial.

The effect of atherosclerosis-induced chronic bladder ischemia on bladder function in the rat.

Increased bladder activity is associated with elevated oxidative stress markers and proinflammatory cytokines in a rat model of atherosclerosis-induced chronic bladder ischemia.

Bladder dysfunction and parkinsonism: current pathophysiological understanding and management strategies.

Drugs and future candidates.

Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011.

Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction.

Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease.

Assessment of Association of Increased Heart Rates to Cardiovascular Events among Healthy Subjects in the United States: Analysis of a Primary Care Electronic Medical Records Database.

Do the urinary bladder and large bowel interact, in sickness or in health? ICI-RS 2011.

Impact of partial urethral obstruction on bladder function: time-dependent changes and functional correlates of altered expression of Ca²⁺ signaling regulators.

β-Catenin signaling contributes to platelet derived growth factor elicited bladder smooth muscle cell contraction through up-regulation of Cx43 expression.

Relationship between expression of β3-adrenoceptor mRNA in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms.

Drugs for lower urinary tract symptoms--anything new?

α-Blockers and antimuscarinics for male lower urinary tract symptoms: the search goes on.

Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia.

Multisystem neuroprosthetic training improves bladder function after severe spinal cord injury.

Functional roles of transient receptor potential melastatin 8 (TRPM8) channels in the cold stress-induced detrusor overactivity pathways in conscious rats.

A nonhuman primate model of stable urinary sphincter deficiency.

The relationship between α1-adrenergic receptors and TRPM8 channels in detrusor overactivity induced by cold stress in ovariectomized rats.

Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder.

Characterization of the early proliferative response of the rodent bladder to subtotal cystectomy: a unique model of mammalian organ regeneration.

Nicotinamide mononucleotide adenylyltransferase 2 (Nmnat2) regulates axon integrity in the mouse embryo.

The effect of the 5-HT2A/2C receptor agonist DOI on micturition in rats with chronic spinal cord injury.

Male lower urinary tract symptoms and α1D-adrenoceptors.

Spinal cord FAAH in normal micturition control and bladder overactivity in awake rats.

Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle.

The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity.

Treatment of lower urinary tract symptoms: agents for intraprostatic injection.

Effect of melatonin on chronic bladder-ischaemia-associated changes in rat bladder function.

Lack of nicotinamide mononucleotide adenylyltransferase 2 (Nmnat2): consequences for mouse bladder development and function.

The effect of in vitro formation of acetylcholine receptor (AChR) clusters in engineered muscle fibers on subsequent innervation of constructs in vivo.

Animal in vivo models of lower urinary tract dysfunction: translational value.

Selective β₃-adrenoceptor agonists for the treatment of overactive bladder.

Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity.

Urothelial signaling.

Long-term structural and functional effects of autologous muscle precursor cell therapy in a nonhuman primate model of urinary sphincter deficiency.

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.

β3-receptor agonists for overactive bladder--new frontier or more of the same?

Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms.

The pharmacology of regenerative medicine.

Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia.

Lamina propria: the functional center of the bladder?

The effect of the 5-HT7 serotonin receptor agonist, LP44, on micturition in rats with chronic spinal cord injury.

Characterization of bladder function in a cannabinoid receptor type 2 knockout mouse in vivo and in vitro.

Effects of allogeneic bone marrow-derived mesenchymal stromal cell therapy on voiding function in a rat model of Parkinson's disease.

Physiological and pharmacological aspects of the vas deferens-an update.

Age-related alterations in regeneration of the urinary bladder after subtotal cystectomy.

The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle.

Bladder function in a cannabinoid receptor type 1 knockout mouse.

Progressive vascular damage may lead to bladder underactivity in rats.

Adipose-derived stem cells (ADSCs) and muscle precursor cells (MPCs) for the treatment of bladder voiding dysfunction.

Bladder underactivity.

Functional consequences of chronic bladder ischemia.

Alpha1 -adrenergic receptors mediate bladder overactivity induced by cold stress in rats with bladder outlet obstruction.

Future therapies: Early trials and basic science.

Downregulation of metabolic activity increases cell survival under hypoxic conditions: potential applications for tissue engineering.

Urinary bladder mucosal responses to ischemia.

Terminology, epidemiology, etiology, and pathophysiology of nocturia.

The many faces of impaired bladder emptying.

Urothelial mucosal signaling and the overactive bladder-ICI-RS 2013.

Correlation of gene expression with bladder capacity in interstitial cystitis/bladder pain syndrome.

Pharmacological treatment of chronic pelvic ischemia.

Is there a peripheral site of action contributing to the voiding effects of α₂-adrenoceptor agonists and antagonists?

Inhibition of smooth muscle force generation by focal adhesion kinase inhibitors in the hyperplastic human prostate.

The use of pharmacotherapy for male patients with urgency and stress incontinence.

Calcium signalling in Cajal-like interstitial cells of the lower urinary tract.

Words of wisdom. Re: Tissue engineering of the bladder: reality or myth? A systematic review.

Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia.

Intraprostatic injections for lower urinary tract symptoms treatment.

Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms.

Mechanisms of ATP release--future therapeutic targets?

Long-term caloric restriction in rats may prevent age related impairment of in vitro bladder function.

Potential of stem cell treatment in detrusor dysfunction.

Differentiated adipose-derived stem cells for bladder bioengineering.

Serotonin (5-HT)2A/2C receptor agonist (2,5-dimethoxy-4-idophenyl)-2-aminopropane hydrochloride (DOI) improves voiding efficiency in the diabetic rat.

Superoxide overproduction and kidney fibrosis: a new animal model.

Functional role of the transient receptor potential melastatin 8 (TRPM8) ion channel in the urinary bladder assessed by conscious cystometry and ex vivo measurements of single-unit mechanosensitive bladder afferent activities in the rat.

The potential utility of non-invasive imaging to monitor restoration of bladder structure and function following subtotal cystectomy (STC).

Translational Research and Functional Changes in Voiding Function in Older Adults.

Transcriptome analysis of bladder biopsy from interstitial cystitis/bladder pain syndrome patients.

Drug therapy of overactive bladder--what is coming next?

Chronic Pelvic Ischemia: Contribution to the Pathogenesis of Lower Urinary Tract Symptoms (LUTS): A New Target for Pharmacological Treatment?

Pharmacology: On the mode of action of mirabegron.

Melatonin Improves Erectile Function in Rats With Chronic Lower Body Ischemia.

Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Fundamentals and clinical perspective of urethral sphincter instability as a contributing factor in patients with lower urinary tract dysfunction--ICI-RS 2014.

Potential Future Pharmacological Treatment of Bladder Dysfunction.

Sensitivity to the thromboxane A2 analog U46619 varies with inner diameter in human stem villous arteries.

Preventive Effects of Long-Term Caloric Restriction on Aging Related In Vivo Bladder Dysfunction and Molecular Biological Changes in the Bladder and Dorsal Root Ganglia in Rats.

Cell versus Chemokine Therapy in a Nonhuman Primate Model of Chronic Intrinsic Urinary Sphincter Deficiency.

The Clock mutant mouse is a novel experimental model for nocturia and nocturnal polyuria.

Hormonal influence on the effect of mirabegron treatment for overactive bladder.

Modulation of Dopaminergic Pathways to Treat Erectile Dysfunction.

Regenerative Medicine Therapies for Stress Urinary Incontinence.

Re: Nonantimuscarinic Treatment for Overactive Bladder: A Systematic Review.

Local versus intravenous injections of skeletal muscle precursor cells in nonhuman primates with acute or chronic intrinsic urinary sphincter deficiency.

Tramadol Abuse and Sexual Function.

Regenerative pharmacology: recent developments and future perspectives.

The link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction.

Determinates of muscle precursor cell therapy efficacy in a nonhuman primate model of intrinsic urinary sphincter deficiency.

Clock Genes Regulate the Circadian Expression of Piezo1, TRPV4, Connexin26, and VNUT in an Ex Vivo Mouse Bladder Mucosa.

Bladder capacity is a biomarker for a bladder-centric versus systemic manifestation in interstitial cystitis/bladder pain syndrome.

Regenerative pharmacology in urology.

Association of lower urinary tract syndrome with peripheral arterial occlusive disease.

Electrospun biodegradable microfibers induce new collagen formation in a rat abdominal wall defect model: A possible treatment for pelvic floor repair?

Can incontinence be cured? A systematic review of cure rates.

On the Site and Mechanism of Action of β3-Adrenoceptor Agonists in the Bladder.

Can we define and characterize the aging lower urinary tract?-ICI-RS 2015.